Kajian klinikal Eksim di Alabama
6 kajian untuk Eksim sedang mencari peserta di lokasi di Alabama.
Bandar di Alabama
Teks kajian rasmi (Bahasa Inggeris)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06947993First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07527923A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Mengambil pesertaFasa 3
Umur 6 hingga 11 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06807268A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
Mengambil pesertaFasa 3
Umur 2 hingga 11 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07599813A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT05995964Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.